Literature DB >> 2832027

Effects of ouabain on isolated cerebral and femoral arteries of the cat: a functional and biochemical study.

J Marín1, C F Sánchez-Ferrer, M Salaices.   

Abstract

1. This study analyzes the mechanisms involved in the responses to ouabain in cat cerebral and femoral arteries and characterizes the electrogenic Na+ pump present in these vessels. The latter was accomplished by measurement of [3H]-ouabain binding to arterial membrane fractions, K+-elicited relaxation and ouabain-sensitive 86Rb+ uptake. 2. Ouabain induced transient contraction in cylindrical segments of cerebral arteries. This contraction was reduced by verapamil (3 X 10(-6) M) and Ca2+-removal from the medium but was not modified by phentolamine (3 X 10(-6) M) or pretreatment with reserpine. However, the contraction elicited by ouabain in femoral artery segments lasted longer, and was reduced by Ca2+-omission, phentolamine or reserpine, but remained unaffected by verapamil. 3. The immersion of the arteries in low-Na+ (25 mM) medium abolished the contraction caused by ouabain. 4. The exposure of the arteries to a K+-free medium induced a small transient increase in tension, and the subsequent application of K+ (7.5 mM) elicited a marked relaxation. This effect was greater in cerebral than in peripheral arteries, and was suppressed by ouabain (10(-4) M). 5. Scatchard analysis of the [3H]-ouabain binding to arterial membrane fractions suggested a single class of binding sites. The KD values for both kinds of arteries were of similar order, while the Bmax value was greater in cerebral than in femoral arteries. 6. Total and ouabain-sensitive 86Rb+ uptakes were greater in cerebral than in femoral vessels. 7. These results indicate that: (1) ouabain-induced contraction of cerebral arteries is due to a direct effect on vascular smooth muscle cells, while in femoral arteries it is due to noradrenaline release from adrenergic nerve terminals; and (2) the electrogenic Na+ pump activity is greater in cerebral than in peripheral arteries.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2832027      PMCID: PMC1853789          DOI: 10.1111/j.1476-5381.1988.tb11403.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  47 in total

Review 1.  Divalent cations as charge carriers in excitable membranes.

Authors:  H Reuter
Journal:  Prog Biophys Mol Biol       Date:  1973       Impact factor: 3.667

2.  Responsiveness to potassium and calcium ions of isolated cerebral arteries.

Authors:  N Toda
Journal:  Am J Physiol       Date:  1974-11

3.  The actions of ouabain on isolated arteries.

Authors:  A Broekaert; T Godfraind
Journal:  Arch Int Pharmacodyn Ther       Date:  1973-06

4.  Electrogenic sodium pump in arterial smooth muscle cells.

Authors:  H Hendrickx; R Casteels
Journal:  Pflugers Arch       Date:  1974       Impact factor: 3.657

5.  Differential effect of verapamil on excitation-contraction coupling in smooth muscle and on excitation-secretion coupling in adrenergic nerve terminals.

Authors:  G Haeusler
Journal:  J Pharmacol Exp Ther       Date:  1972-03       Impact factor: 4.030

6.  Potassium-induced relaxation in isolated cerebral arteries contracted with prostaglandin F2alpha.

Authors:  N Toda
Journal:  Pflugers Arch       Date:  1976-08-24       Impact factor: 3.657

7.  A circulating inhibitor of (Na+ + K+)ATPase associated with essential hypertension.

Authors:  J M Hamlyn; R Ringel; J Schaeffer; P D Levinson; B P Hamilton; A A Kowarski; M P Blaustein
Journal:  Nature       Date:  1982-12-16       Impact factor: 49.962

8.  Ca and ouabain interaction on vascular smooth muscle.

Authors:  A H Briggs; S Shibata
Journal:  Proc Soc Exp Biol Med       Date:  1966-01

9.  Release of noradrenaline from the cat spleen by sodium deprivation.

Authors:  A G Garcia; S M Kirpekar
Journal:  Br J Pharmacol       Date:  1973-04       Impact factor: 8.739

10.  Norepinephrine release in isolated arteries induced by K-free solution.

Authors:  A Bonaccorsi; K Hermsmeyer; C B Smith; D F Bohr
Journal:  Am J Physiol       Date:  1977-02
View more
  8 in total

Review 1.  Endogenous factors with immunological and biological activity similar to cardiac glycosides: biochemical and pathophysiological implications.

Authors:  A Clerico; G Mariani
Journal:  J Endocrinol Invest       Date:  1992-05       Impact factor: 4.256

2.  Corticosteroid modulation of Na(+)-K+ pump-mediated relaxation in maturing airway smooth muscle.

Authors:  C M Schramm; M M Grunstein
Journal:  Br J Pharmacol       Date:  1996-11       Impact factor: 8.739

3.  Alterations in phenylephrine-induced contractions and the vascular expression of Na+,K+-ATPase in ouabain-induced hypertension.

Authors:  Luciana V Rossoni; Mercedes Salaices; Jesús Marín; Dalton V Vassallo; María J Alonso
Journal:  Br J Pharmacol       Date:  2002-02       Impact factor: 8.739

4.  Increased constrictor tone induced by ouabain treatment in rats.

Authors:  Victor M Pulgar; Anne B Jeffers; Hanadi M Rashad; Debra I Diz; Azeez A Aileru
Journal:  J Cardiovasc Pharmacol       Date:  2013-08       Impact factor: 3.105

5.  Early and late contraction induced by ouabain in human umbilical arteries.

Authors:  K Sato; K Aoki
Journal:  Br J Pharmacol       Date:  1991-06       Impact factor: 8.739

6.  Functional role of sodium pump in human placental arteries.

Authors:  M S Fernández-Alfonso; C F Sánchez-Ferrer; M Salaices; J Marín
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1992-01       Impact factor: 3.000

7.  Inhibitory effect of a selective thromboxane A2 receptor antagonist, EP 092, on platelet aggregation in whole blood ex vivo and in vivo.

Authors:  R F Booth; A C Honey; N Lad; D P Tuffin; P J Wade
Journal:  Br J Pharmacol       Date:  1989-02       Impact factor: 8.739

8.  Concentration-Dependent Effects of N-3 Long-Chain Fatty Acids on Na,K-ATPase Activity in Human Endothelial Cells.

Authors:  Roberta Cazzola; Matteo Della Porta; Sara Castiglioni; Luciano Pinotti; Jeanette A M Maier; Benvenuto Cestaro
Journal:  Molecules       Date:  2019-12-28       Impact factor: 4.411

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.